Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, updated its ongoing phase I/II trial testing VAL-083, a bifunctional alkylating agent in development for recurrent malignant glioblastoma multiforme, showing that the therapy is well tolerated, with no drug-related serious adverse events detected in 26 patients treated to date.